The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and impressive returns is clear, the connected risks are also significant. Many of th